Clinical trial · Interventional
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Malignant Neoplasm | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Lung Cancer Metastatic | — | UNRESOLVED | — |
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Urologic Neoplasms | Urinary Tract Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy collection | Procedure | — | UNRESOLVED |
| Blood sample collection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients treated with Immune Checkpoint Blockade
- interventionNames
- Procedure: Blood sample collection
- Procedure: Biopsy collection
Primary outcomes (1)
- measure
- Evaluation of Plasma immunosuppressive actors in patients treated with a Checkpoint inhibitor
- timeFrame
- 4 months
- description
- Measure (by flux cytometry) and comparison of plasma immunosuppressive actors, between baseline and the 4th injection of an Immune Checkpoint inhibitor
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade * Signed informed consent * Affiliated to(or beneficiary of) the French Social Security Exclusion Criteria: * Pregnant or breastfeeding woman or woman who does not apply effective contraception * Emergency * Vulnerable person or unable to provide informed consent * Emergency * Person unable to comply with required study follow up * Contraindication to the study procedure
References
Publications (1)
- RESULTRochigneux P, Lisberg A, Garcia A, Granjeaud S, Madroszyk A, Fattori S, Goncalves A, Devillier R, Maby P, Salem N, Gorvel L, Chanez B, Gukasyan J, Carroll J, Goldman J, Chretien AS, Olive D, Garon EB. Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. Clin Cancer Res. 2022 Dec 1;28(23):5136-5148. doi: 10.1158/1078-0432.CCR-22-1386. PMID 36166003